• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
BYL719

BYL719

Product ID B9700
Cas No. 1217486-61-7
Purity ≥99%, ≥99%ee
Product Unit SizeCostQuantityStock
1 mg $63.00 In stock
5 mg $115.50 In stock
25 mg $173.30 In stock
100 mg $446.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

BYL-719 is an ATP-competitive oral PI3K inhibitor selective for the p110α isoform that is activated by a mutant PIK3CA gene in HER2+ breast cancers and gastric cancers. BYL-719 exhibits anticancer chemotherapeutic activity and inhibits proliferation in a variety of cell lines. IGF1 and neuregulin 1 activate mTOR, a downstream target of PI3K that mediates resistance to BYL-719 in some in vitro cancer models. This compound also decreases invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.

1217486-61-7

Purity

≥99%, ≥99%ee

Formula

C19H22F3N5O2S

Formula Wt.

441.47

Chemical Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

IUPAC Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

Synonym

Alpelisib, NVP-BYL719, BYL-719

Solubility

DMSO 88 mg/mL (199.33 mM) Ethanol 2 mg/mL (4.53 mM) Water Insoluble

Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

B9700 MSDS PDF

Info Sheet

B9700 Info Sheet PDF

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Sci Transl Med. 2013 Jul 31;5(196):196ra99. PMID: 23903756.

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research. 2012.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • T1014

    7-TES-Paclitaxel

    Synthesis impurity

    ≥95%
  • T1008

    10,13-Bissidechain Paclitaxel

    Synthesis impurity

    ≥90%
  • V014451

    Valiltramiprosate

    beta-Amyloid anti-oligomer and aggregation inhi...

    ≥99%
  • B5072

    BMS-754807

    InsR and IGF-1R inhibitor.

    ≥99%
  • F4583

    Flupirtine Maleate

    Kv7 K+ channel activator, NMDA antagonist, GABA...

    ≥98%
  • N8460

    NVP-BHG712

    EphB4 inhibitor.

    ≥98%
  • S8345

    S-(−)-Sulpiride

    GHB agonist, D2/3 antagonist.

    ≥99%
  • P6956

    Prostaglandin E1

    Endogenous prostaglandin, vasodilator.

    ≥98%
  • C0167

    Carbenoxolone

    Synthetic glycyrrhetinic acid derivative; 11β-...

    ≥98%
  • Z161022

    α-Zearalanol

    Mycotoxin that has structural similarity to est...

    ≥98%
  • A1318

    Adenine

    Endogenous purine nucleotide base, required for...

    ≥98%
  • C2997

    Chymostatin

    Protease inhibitor.

    ≥95% (mixture of A, B, C)
  • L9609

    Lycopene

    Carotene pigment found in red and green fruits ...

    ≥90%
  • C1633

    Cefotaxime Sodium

    β-lactam cephalosporin; penicillin binding pro...

    ≥96%
  • D3229

    7,8-Dihydrokawain

    Kavalactone originally found in Piper methystic...

    ≥98%
  • C4417

    Clemizole

    TRPC5 activator, NS4B and histamine H1 inhibito...

    ≥98%
  • K1653

    Kendomycin

    Macrolide; ET antagonist, proteasome inhibitor....

    ≥98%
  • V344761

    Vitamin K2

    2-methyl-1,4-naphthoquinone derivative

    ≥98%
  • D0169

    Darifenacin Hydrobromide

    M3 mAChR antagonist.

    ≥98%
  • B1752

    Benidipine Hydrochloride

    Calcium channel blocker.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only